Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma

Advances in Medical Sciences

Volumn 55, Issue 2, 2010, Pages 266-272

  Ambroszkiewicz, J ^a   Gajewska, J ^a   Klepacka, T ^a   Chelchowska M ^a   Laskowska Klita, T ^a   Wozniak W ^a  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

adolescents; bone metabolism markers; children; osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER SURGERY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOSARCOMA; PATIENT MONITORING; PREOPERATIVE TREATMENT; PROGNOSIS; TREATMENT RESPONSE;

EID: 78650440727     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-010-0043-2     Document Type: Article

References (28)

1. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma: Chemotherapy. Rev Recent Clin Trials. 2008 Sep;3(3):228-31.
2. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma; where do we go from here? Paediatr Drugs. 2008;10(5):315-27.
3. Bacci G, Picci P, Orlandi M, Avella M, Manfrini M, Pignatti G, Dallari D, Manduchi R. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori. 1987 Aug;73(4):331-6.
4. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001 Aug;12(8):1145-50.
5. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treatment with neoadjuvant chemotherapy. Cancer. 2006 Mar1;106(5):1154-61.
6. Demers LM. Biochemical markers in the management of patients with metastatic bone disease. Clin Chem. 1999 Aug;45(8Pt1):1131-2.
7. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000 Jun15;88(12 Suppl):2952-60.
8. Seregni E, Martinetti A, Ferrari L, Bombardieri E. Clinical utility of biochemical marker of bone remodeling in patients with bone metastases of solid tumors. Q J Nucl Med. 2001 Mar;45(1):7-17.
9. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11(4):281-94.
10. Yang L, Grey V. Pediatric reference intervals for bone markers. Clin Biochem. 2006 Jun;39(6):561-8.
11. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, Barr RD. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res. 1996 Nov;11(11):1774-83.
12. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: A 1-year prospective study. J Clin Endocrinol Metab. 1999 Sep;84(9):3174-81. (Pubitemid 30646940)
13. Crofton PM, Ahmed SF, Wade JC, Elmlinger MW, Ranke MB, Kelnar CJ, Wallace WH. Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res. 2000 Oct;48(4):490-6.
14. Bath LF, Crofton PM, Evans AE, Ranke MB, Elmlinger MW, Kelnar CJ, Wallace WH. Bone turnover and growth during and after chemotherapy in children with solid tumors. Pediatr Res. 2004 Feb;55(2):224-30.
15. Zhiping Y, Yanqing H, Guangzhi S, Jianmin L, Xin L. Measurement of bone alkaline phosphatase and relative study with osteosarcoma. Front Med China. 2007 Feb;1(1):54-7.
16. Ferrari S, Zolezzi C, Pratelli L, Fasano MC, Bacci G. Urinary excretion of pyridinium cross-links and serum osteocalcin levels in patients with primary high-grade osteosarcoma. Calcif Tissue Int. 2003;73(1):1-4.
17. Ruza E, Sierrasesumaga L, Azcona C, Patino- Garcia A. Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res. 2006 Jun;59(6):866-71.
18. Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Wozniak W, Laskowska-Klita T. Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma. Pol Merkur Lekarski. 2006 Oct;21(124):330-4. (Pubitemid 44759453)
19. Wasilewski-Masker K, Kastle SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics. 2008 Mar;121(3):705-13.
20. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Rel Res. 2008 Sep;466(9):2114-30.
21. Avnet S, Longhi A, Salerno M, Halleen JM, Perut F, Granchi D, Ferrari S, Bertoni F, Giunti A, Baldini N. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol. 2008 Dec;33(6):1231-8.
22. Holzer G, Krepler P, Koschat MA, Grampp S, Dominkus M, Kotz R. Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br. 2003 Mar;85(2):231-7.
23. Liu PP, Leung KS, Kumta SM, Lee KM, Fung KP. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology. 1996 Jul-Aug;53(4):275-80.
24. Wang J, Pei F, Tu C, Zhang H, Qiu X. Serum bone turnover markers in patients with primary bone tumors. Oncology. 2007;72(5-6):338-42.
25. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer. 2004 Sep20;111(5):783-91.
26. Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninotto M, Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin Chim Acta. 1994 May;226(2):151-8.
27. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccoti P, Dogliotti L, Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. Br J Cancer. 1996 Jun;73(12):1581-7.
28. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphomate therapy. Br J Cancer. 1997;75(3):408-12.